替诺福韦、拉米夫定、依非韦伦联合治疗HBV/HIV合并感染的疗效和安全性

Efficacy and safety evaluation of tenofovir/lamivudine/efavirenz triplet regimen for treatment of HBV/HIV coinfection

目的探讨替诺福韦、拉米夫定、依非韦伦联合方案治疗乙型肝炎病毒/人类免疫缺陷病毒(HBV/HIV)合并感染的疗效和安全性,为临床治疗提供依据。方法对2011年2—10月首次来我院门诊就诊的HIV/AIDS患者进行普查,筛选20例符合条件的HBV/HIV合并感染者入组,予以替诺福韦、拉米夫定、依非韦伦联合抗病毒治疗,观察其疗效和安全性。结果完成48周观察期的15例患者HBV DNA全部阴转,2例出现HBeAg血清学转换,肝功能正常;15例HIV-RNA低于检测下限,CD4+细胞计数平均增加(139.72±3.36)个/μL;肌酐、乳酸均正常,未发生不良事件。结论替诺福韦、拉米夫定、依非韦伦联合治疗HBV/HIV合并感染安全、有效,可作为HBV/HIV合并感染患者常规治疗方案。

Objective To explore the efficacy and safety of tenofovir （TI）F） ＋ lamivudine （3TC） ＋ efavirenz （EFV） combina tion therapy irl the Ireatment of HI3V/HIV coinfeelJon and provide evidence for effective management of HBV/HIV coinfec tion. Methods All the AIDS/H1V patients treated in our hospital from February 2011 to October 2011 were screened for eligi hiliy in this analysis. Twenty eligible patients with HBV/HIV coinfection were treated with the TDF/3TC/EFV triplet regi men. The efficacy and safety of the combination therapy were evaluated. Results of the 15 patients who had completed study period of 48 weeks, all had conversion of HBV DNA to negative, 2 had HBeAg seroconversion. The liver function tests were normal. H1V RNA was below the limit of delection in 15 cases. CD4 ＋ increased by 139, 72 on average, The creati- nine and lactate levels were within normal limits. No adverse events were reported. Conclusions The TI）F/3TC/EFV triplet regimen is safe and effective for treatment of HBV/HIVcoinfection. It is appropriate to recommend this regimen as a standard therapy for HBV/HIV coinfection.